2017
DOI: 10.1111/jhn.12493
|View full text |Cite
|
Sign up to set email alerts
|

Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta‐analysis of randomised placebo‐control human clinical trials

Abstract: How to cite this article AbuMweis S., Jew S., Tayyem R., Agraib L. (2018) Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. J Hum Nutr Diet. 31, 67-84 https://doi.org/10.1111/jhn.12493 AbstractBackground: Over 200 clinical trials have examined the effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplements on risk factors associated with cardiovascular … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

5
58
0
5

Year Published

2017
2017
2021
2021

Publication Types

Select...
6
1
1

Relationship

1
7

Authors

Journals

citations
Cited by 97 publications
(68 citation statements)
references
References 179 publications
(19 reference statements)
5
58
0
5
Order By: Relevance
“…There is good evidence that VLC n-3 PUFAs can favourably modify several biological processes which play a role in promoting atherosclerosis [11], including inflammation [12,13]. These beneficial modifications, which would result in preventing the initiation and slowing the progress of atherosclerosis, include a reduction in endothelium-leukocyte interactions.…”
Section: Introductionmentioning
confidence: 99%
“…There is good evidence that VLC n-3 PUFAs can favourably modify several biological processes which play a role in promoting atherosclerosis [11], including inflammation [12,13]. These beneficial modifications, which would result in preventing the initiation and slowing the progress of atherosclerosis, include a reduction in endothelium-leukocyte interactions.…”
Section: Introductionmentioning
confidence: 99%
“…Hypotensive effect has also been documented with regard to DHA and EPA. Intake of n-3 PUFAs at a dose of over 3 g per day resulted in systolic BP (SBP) decrease of 5.5 mmHg on average and diastolic BP (DBP) drop of 3.5 mmHg on av-erage, and the hypotensive effect of DHA was stronger than one achieved with EPA [11]. The antihypertensive effect of n-3 fatty acids would not be unexpected because one of the concepts possibly explaining pathogenesis of hypertension is the membrane hypothesis.…”
Section: Introductionmentioning
confidence: 99%
“…Eine Erhöhung des Omega-3-Index senkt den Blutdruck und die Herzfrequenz, Triglyzeride und zahlreiche Biomarker der Inflammation, erhöht die Herzfrequenzvariabilität und verbessert die Endothelfunktion; das heißt, mehrere Surrogatparameter bzw. Risikofaktoren für kardiovaskuläre Erkrankungen werden verbessert [2,36]. Auch Intermediärparameter, wie Regression und Progression koronarer Läsionen, oder Parameter der linksventrikulären Struktur und Funktion werden so positiv beeinflusst [19,36].…”
Section: Kardiovaskuläre Präventionunclassified